Trial Profile
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Mezigdomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Celgene Corporation
- 30 Aug 2023 Results presented in the Dana-Farber Cancer Institute Media Release.
- 30 Aug 2023 Results published in the New England Journal of Medicine
- 16 Aug 2023 Planned End Date changed from 30 Jun 2028 to 31 Jan 2028.